Last edition
News about "Immuno-Oncology Therapy"
U.S. Food and Drug Administration accepts sBLA for Ziihera with Priority Review, backed by Phase III data showing improved outcomes in HER2-positive advanced gastric and gastroesophageal cancers.
Immuno-oncology Therapy | 29/04/2026 | By News Bureau
Shilpa Biologicals, mAbTree Biologics to Develop Immuno-Oncology Therapy
Under the terms of the agreement, Shilpa Biologicals will support the entire development process, including first-in-human clinical trials, while also ensuring long-term commercial supply through its Good Manufacturing Practice (GMP) manufacturing capabilities.
Immuno-Oncology Therapy | 19/03/2025 | By Aishwarya | 561
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy